Jobs
-
According to Ocugen, the US National Institute of Allergy and Infectious Diseases (NIAID) will conduct a study comparing the immune response generated by Ocugen’s OCU500 vaccine candidate delivered via inhalation versus OCU500 delivered as a… Read more . . .
-
Oragenics will acquire Odyssey Health’s breath-powered intranasal delivery device and dry powder nasal formulations, in a deal that includes 8 million shares of Oragenics Series F preferred stock and a total of $1 million in… Read more . . .
-
The annual Drug Delivery to the Lungs meeting returns to the Edinburgh International Conference Centre (EICC) December 6-8. DDL 2022 attracted a total of more than 1,000 delegates in person and online, and DDL 2023… Read more . . .
-
Gossamer Bio, which is developing its seralutinib DPI for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Rainer Zimmermann as VP of Medical Affairs. Zimmermann was most recently Global Medical Leader, Pulmonary… Read more . . .
-
According to Codagenix, the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) will provide up to $389 million to support a Phase 2b trial of CoviLiv live attenduated intranasal vaccine as… Read more . . .
-
Pneumagen announced that a Phase 2 challenge study Neumifil multivalent carbohydrate binding module (mCBM) nasal spray against influenza met its primary endpoints, demonstrating statistically significant reductions in the rate of infection and in symptom severity… Read more . . .
-
GH Research announced that the FDA has placed a clinical hold on an IND that the company submitted for GH001 inhaled mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression, citing “Insufficient information to assess risks… Read more . . .
-
Avalyn Pharma announced that an oversubscribed Series C financing brought in $175 million that the company will use for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib for the treatment of pulmonary fibrosis.… Read more . . .
-
The Cystic Fibrosis Foundation announced that it has agreed to provide an additional $9 million in funding for development of Arcturus Therapeutics’ ARCT-032 inhaled mRNA therapy for the treatment of CF. The CF Foundation said… Read more . . .
-
According to Defender Pharmaceuticals, the FDA has accepted the company’s NDA for DPI-386 scopolamine nasal gel for the treatment of motion sickness for priority review, with a PDUFA goal date of January 26, 2024. Defender… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA